ArticlePloS one2026
Association of polycythemia with outcomes of acute decompensated heart failure: A matched and weighted cohort analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe prognostic significance of polycythemia in acute decompensated heart failure (ADHF) is unclear. This study aimed to evaluate the clinical profile and prognostic implications of polycythemia compared with anemia and normocythemia in patients hospitalized with ADHF. MATERIALS AND
methodsWe retrospectively analyzed adult patients hospitalized with ADHF between 2007 and 2017. Patients were categorized by hemoglobin according to World Health Organization criteria: anemic (<13 g/dL men, < 12 g/dL women), normocythemic, or polycythemic (>18.5 g/dL men, > 16.5 g/dL women). Mahalanobis distance matching (MDM; 1:3:3) balanced baseline characteristics, with outcomes compared for in-hospital mortality, 30-day readmission, and long-term survival. Entropy balancing (EBAL) served as sensitivity analysis in the full cohort.
resultsOf 8,332 patients, 5,615 (67.4%) were anemic, 2,639 (31.7%) normocythemic, and 78 (0.9%) polycythemic. Polycythemic patients were younger, predominantly male, and more likely to undergo coronary interventions and receive cardioprotective discharge medications. In the matched cohort (N = 546; 234 anemic, 234 normocythemic, 78 polycythemic), in-hospital mortality rates were similar (5.6%, 3.8%, 7.7%; p = 0.381). One-year mortality was highest in anemia (27.4%) vs. normocythemia (17.5%) and polycythemia (19.2%; p = 0.030). Five-year Kaplan-Meier survival was poorest in anemia, with overlapping curves for polycythemia and normocythemia (log-rank p = 0.027). Cox analysis (reference = normocythemia) showed higher mortality with anemia (HR 1.30, 95% CI 1.03-1.63) but not polycythemia (HR 0.90, 95% CI 0.64-1.27). Post-hoc pairwise log-rank tests (Bonferroni-corrected) confirmed no difference between polycythemia and normocythemia. EBAL-weighted analysis yielded consistent results (log-rank p < 0.001; anemia HR 1.76, 95% CI 1.61-1.92; polycythemia HR 1.14, 95% CI 0.83-1.57).
conclusionsPolycythemia is rare in hospitalized ADHF and, unlike anemia, is not associated with adverse short- or long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.